NASDAQ:XCUR Exicure (XCUR) Stock Price, News & Analysis → Gold Set to EXPLODE! (From Gold Safe Exchange) (Ad) Free XCUR Stock Alerts $0.50 0.00 (0.00%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$0.50▼$0.5250-Day Range$0.50▼$0.7452-Week Range$0.36▼$1.50Volume22,466 shsAverage Volume38,011 shsMarket Capitalization$4.33 millionP/E Ratio0.30Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Exicure alerts: Email Address Exicure MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy2.01% of Float Sold ShortDividend StrengthN/ASustainability-0.67Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$4.49 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.26 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Exicure.Read more about Exicure's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.01% of the float of Exicure has been sold short.Short Interest Ratio / Days to CoverExicure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exicure has recently decreased by 16.00%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldExicure does not currently pay a dividend.Dividend GrowthExicure does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExicure has received a 74.39% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Preclinical research services for mental health", "Clinical research services for cancer", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Exicure is -0.67. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exicure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,488,000.00 in company stock.Percentage Held by InsidersOnly 8.40% of the stock of Exicure is held by insiders.Percentage Held by Institutions42.82% of the stock of Exicure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exicure's insider trading history. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Exicure is 0.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 143.63.Price to Earnings Ratio vs. SectorThe P/E ratio of Exicure is 0.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 182.92.Price to Book Value per Share RatioExicure has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Exicure's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Exicure Stock (NASDAQ:XCUR)Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.Read More XCUR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XCUR Stock News HeadlinesApril 28, 2024 | americanbankingnews.comExicure, Inc. (NASDAQ:XCUR) Short Interest UpdateApril 24, 2024 | investing.comExicure faces Nasdaq non-compliance over delayed filingMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.April 22, 2024 | businesswire.comExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-KFebruary 22, 2024 | benzinga.comExicure Stock (NASDAQ:XCUR), Short Interest ReportFebruary 6, 2024 | benzinga.comWhy FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionFebruary 6, 2024 | msn.comWhy Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving PremarketFebruary 6, 2024 | msn.comExicure Inc Announces Licensing Patents for Therapeutic AdvancementMay 8, 2024 | Manward Press (Ad)Shocking: One AI startup's revenue could surge 4,735%Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner.February 5, 2024 | marketwatch.comExicure, Bluejay Therapeutics Enter Patent License Agreement to Develop Hepatitis TreatmentFebruary 5, 2024 | finance.yahoo.comExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of HepatitisFebruary 1, 2024 | msn.comBest Undervalued Stocks for February 2024December 16, 2023 | ca.finance.yahoo.comExicure, Inc. (XCUR) Stock Price, News, Quote & History - Yahoo FinanceDecember 8, 2023 | investorplace.comWhy Is Exicure (XCUR) Stock Up 57% Today?November 28, 2023 | msn.comExicure receives Nasdaq delinquency notice on late filing of its form 10-QNovember 9, 2023 | morningstar.comExicure Inc XCURAugust 29, 2023 | finance.yahoo.comLacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price DropAugust 23, 2023 | msn.comExicure names new CEO, CFO, directors in wake of resignationsAugust 15, 2023 | finance.yahoo.comExicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)August 11, 2023 | marketwatch.comExicure: Substantial Financing Needed to Continue OperationsAugust 11, 2023 | businesswire.comExicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateJuly 14, 2023 | finance.yahoo.comExicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate UpdateMay 26, 2023 | msn.comExicure board backs CEO Kim's strategic alternative view for companyMay 26, 2023 | finance.yahoo.comExicure, Inc. Announces Support of CEO in its Ongoing Exploration of Strategic AlternativesMay 25, 2023 | sg.finance.yahoo.comExicure, Inc. (XCUR) stock price, news, quote & history – Yahoo FinanceMay 19, 2023 | seekingalpha.comExicure gets Nasdaq non-compliance notice for not filing 10-QApril 27, 2023 | finance.yahoo.comExicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of DirectorsSee More Headlines Receive XCUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exicure and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/19/2021Today5/08/2024Next Earnings (Estimated)7/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:XCUR CUSIPN/A CIK1698530 Webwww.exicuretx.com Phone(847) 673-1700FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio0.30 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$28.83 million Price / Sales0.15 Cash FlowN/A Price / Cash FlowN/A Book Value$3.00 per share Price / Book0.17Miscellaneous Outstanding Shares8,650,000Free Float7,922,000Market Cap$4.33 million OptionableNot Optionable Beta1.31 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Paul Kang (Age 62)CEO & Director Mr. Joshua Miller (Age 48)Chief Accounting Officer Mr. Bart AndersonSenior Director of R&DKey CompetitorsTharimmuneNASDAQ:THARSoligenixNASDAQ:SNGXLongeveronNASDAQ:LGVNEnsysce BiosciencesNASDAQ:ENSCGT BiopharmaNASDAQ:GTBPView All CompetitorsInsidersCo. Ltd. DgpSold 3,400,000 sharesTotal: $4.49 M ($1.32/share)View All Insider Transactions XCUR Stock Analysis - Frequently Asked Questions How have XCUR shares performed in 2024? Exicure's stock was trading at $0.5803 at the beginning of the year. Since then, XCUR stock has decreased by 13.8% and is now trading at $0.50. View the best growth stocks for 2024 here. Are investors shorting Exicure? Exicure saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 151,700 shares, a drop of 16.0% from the March 31st total of 180,600 shares. Based on an average daily trading volume, of 213,100 shares, the short-interest ratio is currently 0.7 days. Currently, 2.0% of the company's shares are sold short. View Exicure's Short Interest. When is Exicure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, July 12th 2024. View our XCUR earnings forecast. How were Exicure's earnings last quarter? Exicure, Inc. (NASDAQ:XCUR) issued its quarterly earnings data on Friday, November, 19th. The company reported ($8.10) EPS for the quarter, missing the consensus estimate of ($2.70) by $5.40. The company had revenue of ($3.68) million for the quarter, compared to analyst estimates of $0.80 million. When did Exicure's stock split? Exicure's stock reverse split on the morning of Thursday, June 30th 2022. The 1-30 reverse split was announced on Thursday, June 30th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Exicure? Shares of XCUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:XCUR) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaAI “wealth window” is closing June 25thParadigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
